Lead Product(s): Undisclosed
Therapeutic Area: Neurology
Highest Development Status: Undisclosed Product Type: Small molecule
Deal Size: $363.3 million Upfront Cash: $3.3 million
Deal Type: Partnership February 17, 2020
The partnership drew on the complementary expertise of Servier and Oncodesign in the fields of neurodegenerative diseases and macrocyclic kinase inhibitors.